CRP and heart disorder: Paramount is the need for assessing whether failed attempts to taper a drug cause any long-term damage in terms of immunogenicity, higher disease activity, structural damage or radiographic progression, or whether increased CRP exposure leads to a higher incidence of cardiac diseases in these patients.